At ONCOWEEK 2020 that will take place in Toulouse on Feb. 3-5, XENOTHERA will present original data from its Glyco-Humanized Polyclonal Antibodies (GH-pAb) platform. Scientists from XENOTHERA found that pAbs raised against given tumor cells show specificity, inhibit tumor growth, synergize with immune checkpoint inhibitors and owing to their mechanism of action induce conversion of cold into hot tumors, i.e. induce tumor infiltration by immune cells. Preclinical data from a hepatocellular carcinoma and other models will be disclosed. After the clinical introduction in 2019 of LIS1, a novel GH-pAb-based induction treatment in Solid Organ Transplantation, these data pave the way for the development of XON-01, an innovative breakthrough therapy against malignancies.
[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment
November 27, 2023. # Download our press release (english version) # Télécharger...More
October 25, 2023. # Download our press release (english version) # Télécharger...More
[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.
September 12, 2023. # Download our press release (english version) # Télécharger...More